Entries |
Document | Title | Date |
20080249061 | Photostable Pharmaceutical Composition Containing Brivudine for the Treatment of Herpetic Keratitis - Ophthalmic composition containing brivudine as active ingredient and a film-forming agent selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and polyacrylate (PA). | 10-09-2008 |
20080269162 | Novel Medicaments for Anti-Retroviral Treatments - This invention relates to the use of a sulphated or phosphated polysaccharide for the preparation of a medicine for treatments against retroviruses, more particularly against lentiviruses and oncoviruses, and particularly against HIV, including strains of these retroviruses that are resistant to known anti-retroviral agents; this medicine acts on the replication cycle of said retroviruses by inhibition of their RT. | 10-30-2008 |
20080300216 | Dutpase Inhibitors - Deoxyuridine derivatives of Formula (I′); where A is O, S or CH | 12-04-2008 |
20090023680 | Fixed ratio drug combination treatments for solid tumors - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors. | 01-22-2009 |
20090029939 | Pre-organized tricyclic integrase inhibitor compounds - Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. | 01-29-2009 |
20090105187 | METHODS OF TREATING LENTIVIRUS INFECTION - The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a cell; and compositions comprising the agents. The present invention further provides methods of reducing the mutation rate of a lentivirus in a cell; and methods of reducing the emergence of drug-resistant strains of lentivirus. The present invention further provides methods for treating lentivirus infections. | 04-23-2009 |
20090105188 | Compositions and Methods for Treating Necrotizing Enterocolitis - The present invention relates to a method for treating or preventing necrotizing enterocolitis (NEC) in a human neonate in need thereof, comprising administering to the neonate a pharmaceutically effective amount of a composition comprising a poly(ADP-ribose) synthetase/polymerase (PARP) inhibitor. Also contemplated herein is an infant food or treatment composition comprising a PARP inhibitor in an amount that is 5 to 500 times greater than a daily recommended intake dosage for the PARP inhibitor. | 04-23-2009 |
20090118224 | AGENT AGAINST PSYCHOSOCIAL STRESSES - To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates psychosocial stress. | 05-07-2009 |
20090137522 | Pharmaceutical Composition on Basis of Reverse Transcriptase Inhibitor and Meldonium - Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor. | 05-28-2009 |
20090156548 | FLUOROCYTIDINE DERIVATIVES AND COX-2 INHIBITORS FOR THE TREATMENT OF CANCER - The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient. | 06-18-2009 |
20090197827 | Combination Therapy for Treatment of FIV Infection - The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor. | 08-06-2009 |
20090221523 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses - A method for the prevention or treatment of poxvirus infection by administering an effective amount of an antiviral agent comprising cyclopropanated carbocyclic 2′-deoxynucleoside to an individual in need thereof is provided. | 09-03-2009 |
20090239817 | ORGANIC THIOPHOSPHATE ANTIRETROVIRAL AGENTS - A method for the prevention or treatment of human immunodeficiency virus infection by administering an effective amount of amifostine, phosphonol, or similar compound to an individual in need is provided. | 09-24-2009 |
20090281053 | NOVEL CRYSTALLINE FORM OF LAMIVUDINE - The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (−) cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one in the form of monoclinic crystals has characteristic powder X-ray diffractogram, as disclosed herein, is disclosed along with a process for preparation of the same. A pharmaceutical composition in solid dosage unit form comprising a therapeutically effective amount of a new Lamivudine polymorphic form in combination with a pharmaceutically acceptable carrier is also disclosed along with a pharmaceutical composition useful for treating HIV infections in humans. | 11-12-2009 |
20090281054 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES - Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis are provided. In particular, methods and compositions comprising substituted derivatives of capuramycin analogs for the treatment of infectious diseases are provided. Also provided are capuramycin analogue formulations comprising PEGylated compounds, including a PEGylated vitamin E derivative, liposomes and nanoparticle carriers. The invention provides methods and compositions comprising a capuramycin analogue and capuramycin analogues in combination with one or more other active agents. | 11-12-2009 |
20090286755 | POTENTIATOR OF RADIATION THERAPY - To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. | 11-19-2009 |
20100029580 | Method for Diagnosing Non-Small Cell Lung Carcinoma - The present invention relates to the constitutive activity of the Hedgehog pathway in non-small cell lung carcinoma (NSCLC). A method for diagnosing NSCLC by detecting the level of a component of the Hedgehog pathway is provided, as is a method for identifying subjects that will respond positively to treatment with a Hedgehog pathway antagonist. Methods for treating subjects with cancer or cancers resistant to Hedgehog pathway antagonists are also provided. | 02-04-2010 |
20100041620 | METHODS FOR IMPROVING FRONTAL BRAIN BIOENERGETIC METABOLISM - The invention provides methods and compositions for augmenting bioenergetic metabolism in the frontal brain involving administration of a cytidine-containing or uridine-containing compound to a human. | 02-18-2010 |
20100048504 | CRYSTALLINE AND AMORPHOUS FORMS OF BETA-L-DEOXYTHYMIDINE - Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B. | 02-25-2010 |
20100075917 | THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS - The invention relates to a pharmaceutical composition containing as an active ingredient at least one compound selected from the compounds of the formula (II), in which the S atom is bonded to the nucleoside carbon at T or to the nucleoside carbon at 3′, and from the compounds of the following formula (III): formulae in which B is a nucleotide natural or modified base, x is 0, 1 or 2, and R1 and R represent a carbonated group or a molecular hydrocarbon remnant that can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si, X where X is halogen. The invention also relates to pharmaceutically acceptable carrier. | 03-25-2010 |
20100130439 | GENOMIC MUTATION INHIBITORS THAT INHIBIT Y FAMILY DNA POLYMERASES - Modulators of error prone DNA polymerases are provided. Methods of inhibiting genomic mutation to inhibit the emergence of drug resistant target cells are also provided. Screening assays for identifying modulators of error prone DNA polymerases are provided. | 05-27-2010 |
20100130440 | ANTIVIRAL NUCLEOSIDES - Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus. | 05-27-2010 |
20100144665 | TREATMENT OF STATIN SIDE EFFECTS - The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, eg Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods. | 06-10-2010 |
20100168052 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 07-01-2010 |
20100184717 | Treatment of Statin Side Effects Using Uridine Derivatives - The invention relates generally to treatment of muscle pain and/or fatigue and to methods of treatment of side effects of statin therapy which involve the administration of uridine, biological precursors or derivatives or uridine or salts, esters, tautomers or analogues thereof, which are collectively referred to as uridine related compounds. The invention is also directed to compositions, uses and combination packs or kits related to the treatment method. | 07-22-2010 |
20100197629 | ORAL PHARMACEUTICAL SOLUTIONS CONTAINING TELBIVUDINE - A pharmaceutical solution suitable for oral administration comprising β-L-thymidine/2′-deoxy-L-thymidine (telbivudine), a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents, a preservative system, and a buffer system suitable to allow both drug stability and preservation. | 08-05-2010 |
20100222296 | PYRIMIDINES, SUCH AS URIDINE, IN TREATMENTS FOR PATIENTS WITH BIPOLAR DISORDER - The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder. | 09-02-2010 |
20100261669 | UNIT DOSAGE FOR BRAIN HEALTH - The invention pertains to a composition comprising (i) uridine in nucleobase, nucleoside and/or nucleotide form; (ii) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); and (iii) a tocopherol and/or an equivalent thereof, wherein said composition has: a) a weight of 200-3000 mg per unit dose; b) an energy content of less than 50 kcal per unit dose; and/or c) a volume between 0.1 and 10 ml per unit dose. The invention also pertains to the use of such composition in reducing abeta plaque burden and neurodegeneration, in the treatment of diseases related with imparted nerve functioning, in particular dementia, Alzheimer's disease and memory disorders. | 10-14-2010 |
20100261670 | COMPLEXES OF PHOSPHATE DERIVATIVES - There is provided a composition comprising the reaction product of:
| 10-14-2010 |
20100273733 | HIV Treatment - The invention is directed to a method of treating an HIV infection comprising administering an aminoalkanol and a glucocorticoid. The invention is also directed to a pharmaceutical composition comprising the aminoalkanol and the glucocorticoid in amounts effective to selectively eliminate HIV-infected cells and/or to inhibit HIV replication. A method of enhancing the anti-HIV effect of the antiretroviral drug AZT by administering with the AZT, a pharmaceutical composition comprising an aminoalkanol and a glucocorticoid. | 10-28-2010 |
20100279977 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them. | 11-04-2010 |
20100323981 | TREATMENT OF STATIN SIDE EFFECTS - The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods. | 12-23-2010 |
20100331275 | SUPPORTING ACTIVITIES OF DAILY LIVING - The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; u se of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping. | 12-30-2010 |
20110039800 | PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS - The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar. | 02-17-2011 |
20110053884 | POTENT COMBINATIONS OF ZIDOVUDINE AND DRUGS THAT SELECT FOR THE K65R MUTATION IN THE HIV POLYMERASE - Combinations of antiretroviral nucleoside reverse transcriptase inhibitors, and methods for their use in treating retroviral infections, are provided. In one embodiment, the combinations include non-thymidine nucleoside antiretroviral agents, such as tenofovir-DF, abacavir, APD and DAPD, that select for the K65R mutation and relatively low doses of zidovudine (AZT) or other thymidine nucleoside antiretroviral agents. The thymidine nucleoside antiretroviral agents retard development of the K65R mutation, and at the low doses, are less likely to produce side effects. In another embodiment, the combinations include DAPD and AZT. DAPD retards the development of TAMs, and AZT retards the development of the K65R mutation. In a third embodiment, the combinations include adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient. | 03-03-2011 |
20110092453 | TREATMENTS AND PREVENTION OF HYDROCEPHALUS - The present invention relates to the prevention or treatment of hydrocephalus. In one embodiment, the invention includes the use of one or more bioavailable folate derivatives, or salts thereof, for the prevention or treatment of hydrocephalus. Examples of more bioavailable folate derivatives that may be used include any combination of: folinic acid, tetrahydrofolate, thymidine, 10-formyltetrahydrofolate or methyltetrahydrofolate, or salts thereof. The invention also relates to a composition comprising two or more bioavailable folate derivative(s); for example, folinic acid and tetrahydrofolate. | 04-21-2011 |
20110144051 | Compositions and methods for treatment of mitochondrial diseases - Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. | 06-16-2011 |
20110160158 | METHODS OF TREATMENT OF BIPOLAR DISORDER - A method of treating an individual diagnosed with bipolar disorder, comprises determining the number of manic episodes and/or depressive episodes experienced by an individual exhibiting one or more symptoms of bipolar disorder (e.g., bipolar disorder I); and if the number of manic episodes and/or the number of depressive episodes is each 2 or greater (e.g., 3 or greater, 4 or greater, 5 or greater, 6 or greater, 10 or greater, or 15 or greater), administering to the individual an effective amount of a uridine composition. | 06-30-2011 |
20110166096 | URACIL DERIVATIVES AND USE THEREOF - Disclosed are uracil derivatives of the formula (I): | 07-07-2011 |
20110172178 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES - It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. | 07-14-2011 |
20110183933 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS - In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits. | 07-28-2011 |
20110263526 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents - The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs. | 10-27-2011 |
20110269709 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS - The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I. | 11-03-2011 |
20120010165 | POTENTIATOR OF RADIATION THERAPY - To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. | 01-12-2012 |
20120077772 | SOLID ORAL DOSAGE FORMS OF LAMIVUDINE - The present invention relates to the oral solid pharmaceutical composition comprising lamivudine or a pharmaceutically acceptable salt thereof with isomalt as a filler. The present invention also relate to the combination of lamivudine and other Anti-HIV agents. Thus, for example, the present invention provides a stable tablet formulation comprising lamivudine, isomalt, crospovidone, calcium stearate and opadry white. | 03-29-2012 |
20120115807 | COMBINATION OF ALOVUDINE AND ZIDOVUDINE IN A MOLAR RATIO OF 1:100 TO 1:350 - Co-administration of alovudine and zidovudine at ratios considerably in excess of the prior art completely or substantially abolishes the mitochondrial toxicity of alovudine in mitochondrial DNA depletion experiments. The invention thus provides pharmaceutical compositions comprising alovudine and zidovudine in a molar ratio in the range 1:100 to 1:350 and methods for the treatment or prophylaxis of multiply resistant HIV comprising the simultaneous or consequential administration of alovudine and zidovudine in the characteristic molar ratio. | 05-10-2012 |
20120129800 | Agent For Preventing And Treating Pityriasis Versicolor - The present invention concerns an agent for prevention and treatment of pityriasis. | 05-24-2012 |
20120135954 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF - Described herein are compounds and methods that prevent the viral infection of cells. The compounds and methods described herein minimize viral resistance and maximize the number of targeted viruses. Additionally, the compounds and methods minimize the toxicity toward uninfected cells. | 05-31-2012 |
20120142627 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV and HBV, in human patients or other animal hosts. The compounds are certain 6-substituted-2-amino-purine dioxolane monophosphates or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. | 06-07-2012 |
20120165288 | AZAPEPTIDE DERIVATIVES - This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir. | 06-28-2012 |
20120225836 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF - Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly. | 09-06-2012 |
20120225837 | MEDICINAL AGENT FOR DISEASE ASSOCIATED WITH EPSTEIN-BARR VIRUS, AND METHOD FOR SCREENING OF THE MEDICINAL AGENT - 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity. | 09-06-2012 |
20120225838 | ANTI-TUMOR EFFECT POTENTIATOR - There is provided an agent for potentiating the effects of an anti-tumor agent. | 09-06-2012 |
20120258929 | AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT PEPTIDYL-DIPEPTIDASE A ACTIVITY - The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect peptidyl-dipeptidase A; a method for assaying pesticidal activity of a test substance, which comprises a step of measuring the activity of a peptidyl-dipeptidase A in a reaction system in which the peptidyl-dipeptidase A contacts with a test substance, and the like. | 10-11-2012 |
20130059812 | COMPOSITION FOR TREATING CHRONIC HEPATITIS B, CONTAINING CLEVUDINE AND ADEFOVIR DIPIVOXIL - The present invention relates to a composition for treating chronic hepatitis B, containing clevudine and adefovir dipivoxil. The combined formulation of the present invention maximizes the effect for treating diseases caused by infection of hepatitis B virus and shows a mutual inhibitory activity against a resistant virus compared with a single-component formulation. | 03-07-2013 |
20130157973 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL INFECTIONS AND DISORDERS - Methods of treating gastrointestinal disorders, in a patient in need thereof, including disorders of the liver and pancreas, using an amount of an orally dosed TLR-7 compound in an amount sufficient to increase IFN in the gastrointestinal area, including the liver, but not significantly increasing systemic IFN. | 06-20-2013 |
20130217646 | COMBINATION OF ALOVUDINE AND ZIDOVUDINE IN A MOLAR RATIO OF 1:100 TO 1:350 - Co-administration of alovudine and zidovudine at ratios considerably in excess of the prior art completely or substantially abolishes the mitochondrial toxicity of alovudine in mitochondrial DNA depletion experiments. The invention thus provides pharmaceutical compositions comprising alovudine and zidovudine in a molar ratio in the range 1:100 to 1:350 and methods for the treatment or prophylaxis of multiply resistant HIV comprising the simultaneous or consequential administration of alovudine and zidovudine in the characteristic molar ratio. | 08-22-2013 |
20130303479 | Antiretroviral Cyclonucleoside Compositions and Methods and Articles of Title of Invention Manufacture Therewith - ASPECTS OF EMBODIMENTS RELATE TO methods of treating human immunodeficiency virus (HIV) infection. Further aspects of embodiments also relate to constellations of compositions for treating HIV infection. Still additional aspects of embodiments relate to a many methods of making compositions useful in the treatment of HIV infection. | 11-14-2013 |
20130310335 | PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS - The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar. | 11-21-2013 |
20140080784 | USE OF URIDINE AND DEOXYURIDINE TO TREAT FOLATE-RESPONSIVE PATHOLOGIES - The present invention relates to a pharmaceutical or dietary composition comprising deoxyuridine and a pharmaceutically or dietetically suitable carrier. Another aspect of the present invention relates to a method of supplementing the dietary needs of a subject. This method includes administering to the subject a dietary supplementing effective amount of deoxyuridine. Yet another aspect of the present invention relates to a method of treating cancer in a subject. This method includes selecting a subject having cancer and administering to the selected subject a therapeutically effective amount of uridine, thereby treating the cancer in the selected subject. | 03-20-2014 |
20140100188 | PHENOTYPING TUMOR-INFILTRATING LEUKOCYTES - The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient. | 04-10-2014 |
20140107062 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS - The present invention provides compositions and methods for treating or preventing diseases associated with vascular and non-vascular body passageways, the method comprising the step of delivering to a body passageway a therapeutic agent delivered locally through a polymer matrix from an implanted stent or other structure. | 04-17-2014 |
20140187510 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed. | 07-03-2014 |
20140256670 | AZIDOTHYMIDINE QUINOLINE CONJUGATED COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN ANTI-HEPATOMA THERAPY - The invention provides Zidovudine conjugated quinoline compound N-((1-(2-(Hydroxy-methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8a-hexahydrodibenzo[a,c]phenazin-2-yloxy)hexanamide. The compound can selectively kills the hepatoma cells especially the hepatoma cells with hepatitis B, and inhibit the growth of subcutaneous tumors in mice, but has no significant toxicity to normal liver cells. Experiments confirm the compound has anti-hepatoma effect, and can be used in preparation of anti-hepatoma drugs. | 09-11-2014 |
20140274939 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES - Kits and methods for treating disordered tissue caused by a virus in a mammal involve co-administration of a systemic anti-virus drug and topically administering an anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the disordered tissue surface and allow the anti-infective agent to kill viruses at the disordered tissue site. The anti-infective composition reduces the time and/or number of dosages required for the systemic anti-virus drug to treat the disordered tissue in the absence of topically administering the anti-infective composition. It also reduces or eliminates incidences of post-treatment neuralgia. | 09-18-2014 |
20140303112 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) - The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity. | 10-09-2014 |
20140323427 | URIDINE AND URIDINE ANALOGUES FOR TREATMENT OF SPECIFIC LUNG DISEASES, NAMELY COPD AND PULMONARY FIBROSIS - The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogues. | 10-30-2014 |
20140336143 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 11-13-2014 |
20140364389 | Combination Therapy - The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. | 12-11-2014 |
20140371167 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE - This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P | 12-18-2014 |
20150087614 | METHODS AND COMPOSITIONS FOR REDUCING THE PROLIFERATION OF GRAM POSITIVE BACTERIA - Provided herein are methods for inducing cell death in a gram positive bacterium and methods for reducing the proliferation of a gram positive bacterium that include contacting a gram positive bacterium with a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are methods of treating a subject having a gram positive bacterial infection that include administering to a subject having a gram positive bacterial infection a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are compositions containing a dye (e.g., an azo dye) and a TarO inhibitor, and kits containing at least one of these compositions. | 03-26-2015 |
20150105342 | IN VITRO METHOD FOR PREDICTING DISEASE OUTCOME IN STAGE II COLORECTAL CANCER - The present invention relates to a method for determining the likelihood of disease outcome of a patient diagnosed with microsatellite stable, stage II colorectal cancer. More in particular, the present invention relates to a method for determining the prognosis of a patient diagnosed with microsatellite stable, stage II colorectal cancer wherein the CpG island methylation status of the promoter of the CHFR gene is determined and wherein methylation of the promoter is indicative of a poor prognosis. | 04-16-2015 |
20150374704 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE - Compositions and methods for treating disordered and/or prodromal stage tissue infected with by a virus in a mammal by co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at a treatment site. The topical anti-infective composition enhances efficacy of the systemic anti-virus drug and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the viral infection. The topical anti-infective composition can be more beneficial than the systemic anti-virus drug in killing viruses and can reduce or eliminate post-herpetic neuralgia. | 12-31-2015 |
20160015731 | A TOPICAL ANTIVIRAL COMPOSITION CONTAINING A LOCAL ANESTHETIC AND METHOD OF MAKING THE SAME - The present invention provides a novel pharmaceutical composition and method of making the same. The composition comprises an effective amount of an antiviral agent and a local anesthetic. The antiviral drug can be sorivudine. The local anesthetic can be lidocaine or its pharmaceutically acceptable salt. Herpes virus infections in humans can be caused by different human herpes viruses, the most common being herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV). | 01-21-2016 |
20160045530 | ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE - Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. | 02-18-2016 |
20160075731 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE - This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P | 03-17-2016 |
20160082031 | ANTITUMOR AGENT INCLUDING LOW-DOSE IRINOTECAN HYDROCHLORIDE HYDRATE - Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. | 03-24-2016 |
20160082032 | THERAPEUTIC EFFECT PREDICTION METHOD FOR COLORECTAL CANCER PATIENT IN WHOM EXPRESSION OF TK1 PROTEIN HAS INCREASED - The present invention provides a method for predicting the therapeutic effect of chemotherapy using an antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the following steps (1) to (3). As the means for solving the problem, the following invention is provided: a method comprising (1) detecting the expression of TK1 protein by an immunohistochemical method in tumor cells contained in a biological sample obtained from the patient; (2) based on the detection results obtained in step (1), classifying the tumor cells into positive cells and negative cells, and calculating the percentage of positive cells in the tumor cells; and (3) based on the calculation results obtained in step (2), predicting that when the percentage is 30% or more, the patient is likely to sufficiently respond to chemotherapy using the antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. | 03-24-2016 |
20160101188 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS - Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes β-cyclodextrin. The nucleobases and nucleotides are conjugated to the β-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/nucleobase or nucleotide conjugate to cancer cells. The DDS/nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer. | 04-14-2016 |
20160120893 | METHODS AND COMPOSITIONS RELATING TO MODULATION OF THE PERMEABILITY OF THE BLOOD BRAIN BARRIER - Described herein are methods and compositions relating to modulating the permeability of the blood-brain barrier, e.g. increasing or decreasing the permeability of the blood-brain barrier for therapeutic purposes. | 05-05-2016 |
20160136134 | ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR - Provided are compounds antiviral compounds represented by formula Ia and Ib: | 05-19-2016 |
20160151494 | TARGETING THYMIDINE KINASE PHOTOSENSITIZER AND PHARMACEUTICAL COMPOSITION AND USE FOR CANCER TREATMENT THEREOF | 06-02-2016 |
20160152573 | BIOORTHOGONAL METHODS AND COMPOUNDS | 06-02-2016 |
20160152655 | 2', 3'- DIDEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | 06-02-2016 |
20160159843 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES - The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: | 06-09-2016 |
20220135611 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE - This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P | 05-05-2022 |